MedTrace Logo

Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women

NCT00056082 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2017-02-15

No results posted yet for this study

Summary

RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing breast cancer in at-risk women.

PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing breast cancer in premenopausal women who are at risk of developing cancer.

Conditions

Interventions

DRUG

celecoxib

Celecoxib daily for 12 months

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Carol J. Fabian, MD · University of Kansas

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2008-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00056082 on ClinicalTrials.gov